Drug design for neuroscience
Alan P. Kozikowski · 1993
Neurotransmitter receptors as pharmacological targets in Alzheimer's disease - design of drugs on a rational basis, Povi Krogsgaard-Larsen the design and synthesis of BMY 21502 - a potential memory and cognition enhancing agent, Ronald J. Mattson and Joseph P. Yevich muscarinic agonists for the central nervous system, Raymond Baker and Angus M. MacLeod novel organic reactions in the search for anxioselective anxiolytics at the benzodiazepine receptor, Weijiang Zhang and James M. Cook design of orally active dopamine autoreceptor agonists, Lawrence D. Wise and Juan C. Jaen 3 Beta-[substituted phenyl]tropan-2-carboxylic acid ester analogues of cocaine - synthesis, biochemical and pharmacological properties, F. Ivy Carroll et al serotonin receptors, agents and actions, Jeffrey L. Herndon and Richard A. Glennon studies of a novel series of thiazole-containing 5-HT3 receptor antagonists, Terry Rosen et al conformationally constrained acidic amino acids as probes of glutamate receptors and transporters, Richard Bridges and Richard Chamberlin L-2-[carboxycyclopropyl]glycines - conformationally constrained L-glutamate analogues, Yasufumi Ohfune and Heruhiko Shinozaki design and synthesis of conformationally constrained acidic amino acids as NMDA receptor antagonists, Paul L. Ornstein modulation of the NMDA receptor complex - design and synthesis of competitive NMDA antagonists and PCP-site ligands, Christopher F. Bigge et al glycine-site N-methyl-D-aspartate receptor antagonists, Paul D. Leeson synthetic inositol 1,4,5-triphosphate affinity-chromatography - fishing out novel ins(1,4,5)P3- recognizable proteins, Schoichiro Ozaki et al chemical approaches to brain-targeting of biologically active compounds, Marcus E. Brewster.